摘要
肺癌是世界上最常见的恶性肿瘤,其发病率和死亡率逐年上升,其中,NSCLC占大多数。肺癌早期可以采用外科手术,但术后仍有较高复发率,多数患者术后仍需接受放化疗治疗。近年来,分子靶向药物在肺癌临床治疗中取得突破性进展,但长期应用抗肿瘤靶向药物治疗对远期临床症状缓解及预后并无明显改善,且易导致肿瘤耐药性。EHD1与EGFR突变通过干扰细胞内吞循环,造成细胞多种蛋白受体转导及多种信号通路传导异常,诱发细胞癌变。EHD1和EGFR有望成为NSCLC治疗新靶点,探索二者异常表达在NSCLC中的具体机制,为新型抗肿瘤靶向药物研制提供重要理论基础,为肺癌临床诊治提供新的诊疗方案,对改善患者病情及提高生存率等方面,具有深远意义。
Lung cancer is the most common malignant tumor in the world. The incidence and mortality of lung cancer is increasing year by year,and NSCLC is the most common cancer. Surgical procedures can be used in the early stage of lung cancer,but postoperative recurrence rate is still high,most patients still need to accept some chemotherapy. In recent years,the molecular target drug in the treatment of lung cancer achieved a breakthrough. However,long- term use of antitumor target to drug treatment on long- term clinical symptom remission and prognosis are not improved significantly,and easily lead to drug resistance. EHD1 and EGFR mutations interfere with the cell cycle,causing cell multiple protein receptor transduction and abnormal signal transduction pathway,and induce cell malignant transformation. EHD1 and EGFR is expected to become a new target in the treatment of NSCLC,to explore abnormal expression in NSCLC specific mechanisms,for new antitumor target to drug research and development to provide an important theoretical basis,provide a new treatment for the clinical diagnosis and treatment of lung cancer,with far- reaching significance to improve the patient＇s condition and improve the survival rate.
出处
《现代肿瘤医学》
CAS
2017年第4期669-672,共4页
Journal of Modern Oncology
基金
黑龙江省青年科学基金项目(编号:QC2011C047)
黑龙江省教育厅科学技术研究项目(编号:12511z014)
